Kannalife, Inc.’s Post

💥💥New Publication Alert💥💥 I'm excited to share our newly published paper titled "Progress of Phage Therapy Research as an Alternative to Antibiotics: Current Status, Challenges, and The Future of Phage Therapeutics". I appreciate the big contributions of my co-authors: Samuel Awoniyi, Bisola Bolarinde, and Awotimiro Oluwafemi I also acknowledge the support of the Young Researchers' Hub - OAU, under the leadership of Taiwo Sokunbi. Here's the link to the full article: https://lnkd.in/eE8SVa83 #publichealth #AMR #phagetherapyawareness #bacteriophages

Drug development is challenging – a lot of drugs in development don’t make it to market. Limited reliability of biomarker data can be one of many struggles that drug developers face. In this clip, Ernestas Sirka, Chief Scientific Officer at Inoviv, describes how they address common challenges to drug development success. One innovative solution is combining Immunoprecipitation with Mass Spectrometry (IP-MS). Discover how the groundbreaking NeuroKey-3™ assay is accelerating neurodegenerative drug discovery and development in the full webinar, available on-demand: https://hubs.li/Q02zkVc_0 #Proteomics #MassSpec #DrugDiscovery #DrugDevelopment #AlzheimersDisease #BiotechWebinar

📑 Work Packages. #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials. Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain. Are you curious about AVITHRAPID's WP2 ( INSTITUT NATIONAL DE RECHERCHE EN SCIENCES ET TECHNOLOGIES POUR L'ENVIRONNEMENT ET L'AGRICULTURE – France)? Take a look below! 🔎 👇

As we look back at the past month, we want to highlight Bulmore's blog, which captures a series of remarkable achievements in the pharmaceutical and editorial space. 🌐 Highlighted in our latest blog post is our recent collaboration on a pivotal publication about pandemic preparedness, where Marie Beitelshees from Bulmore provided editorial support. This article, published by Pfizer, underscores the critical role of global collaboration in pandemic preparedness. 📚 Beyond this, our blog also features insights from two other significant publications - a second piece on pandemic preparedness and an innovative review in RNA in synthetic biology. These works collectively showcase Bulmore's dedication to scientific excellence and our ability to support diverse thought leadership needs in pharma. 👩🔬🧬 These publications are not just milestones for Bulmore but are also crucial contributions to global health and scientific knowledge. Dive into our blog for a detailed look at these accomplishments and how they align with our commitment to advancing thought leadership. #Bulmore #editorialservices #PandemicPreparedness #SyntheticBiology

📅 Save the Date: September 7th! Join us for the second in a series of Oncofactory’s webinars showcasing new ERBC's innovative technology platform for the evaluation of novel anticancer agents. Our platform is based on an #avian embryo patient-derived xenograft (AVI-PDX) model developed and patented by Oncofactory, an ERBC Group company. This interactive webinar will answer your burning questions about the real-world application of the AVI-PDX model. With Valerie Castellani Lincontang, PhD, Founder and Chief Scientific Officer of Oncofactory, and guest speaker Karine Aguera, Chief Development Officer at StromaCare, previously R&D Project leader at ERYTECH Pharma. 👉 Register here: https://lnkd.in/e9rJWMFA Not available? Register anyway and get access to the session replay. Also, mark your calendars for our third webinar on September 28, 2023, where we will delve into clinical case studies. (Link to register: https://lnkd.in/eWn5hBEF) See you soon. For more information on the Oncofactory platform overview and to view the Webinar 1 replay, click here: https://lnkd.in/eYhXF2Ns #Lifescience #testing #efficacy #research #PDXmodel #invivomodels #CRO #drugdevelopment #ethicalpractice #NAM #nonclinical #biotech #TNBC

⚗ #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials.  🤳 Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. 🔬 The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain. 🔎 Are you curious about AVITHRAPID's WP7 (Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung) ? 👀 Take a look below! 👇 📑 Work Packages

Excellent approach to increase human-relevant modeling and reduce animal model use by applying breakthrough organoid technology at an unprecedented scale.

The speakers are announced for the 10th Novalix Conference #AnniversaryEdition, focusing on "Reinventing Drug Discovery, from Retrospective to Perspectives"!

🔎 Are you curious about AVITHRAPID's WP6 (Chelonia Applied Science SA) ? 👀 Take a look below! 👇 📑 Work Packages ⚗ #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials. 🤳 Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. 🔬 The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain.